Short answer
TriSalus Life Sciences, Inc. (TLSI) filed its Q3 2026 10-Q quarterly report on Nov 10, 2026 for the quarter ended Sep 30, 2026. Quarterly revenue was $13M (up 11.3% year over year) with net income of −$9M.
Q3 2026 key financials · XBRL
- Revenue
- $13M
- +11.3% YoY · +12.9% QoQ
- Net income
- −$9M
- +18.1% YoY · +3.6% QoQ
- Operating margin
- -59.9%
- Gross margin
- 86.2%
- EPS (diluted)
- −$0.15
- +86.0% YoY · +11.8% QoQ
Source: XBRL data from the TriSalus Life Sciences, Inc. (TLSI) Q3 2026 10-Q on SEC EDGAR. USD.
TriSalus Life Sciences, Inc. Q3 2026 10-Q analysis
AI summary of MD&A and risk factor updates
Management Discussion & Analysis
- Q3 revenue $12.878M, up 11.3% YoY from $11.566M, driven by higher TriNav unit sales
- Gross margin 86.2% vs 83.5% YoY, with gross profit $11.095M vs $9.660M
- Sole TriNav product line, revenue growth driven by increased units and lower per-unit costs
- Cash $41.1M vs $20.4M at December 31, 2025, with nine-month operating cash use $21.884M
- $42.6M net public-offering proceeds, ongoing operating losses and need for additional capital highlighted as headwinds
Risk Factors
- No material changes from the December 31, 2025 Form 10-K risk factors
- Continued clinical-development risk, potential delays or unfavorable trial outcomes
- Continued regulatory risk, failure to obtain or maintain required approvals
- Continued liquidity risk, need for additional financing to support operations
- Continued commercialization risk, limited market acceptance of TriSalus products
Generated from the filing text; verify against the original. 10-K vs 10-Q vs 8-K
Other TriSalus Life Sciences, Inc. quarterly reports
Ask about this quarter
Compare quarters, check guidance or see what insiders and funds did around the report.